Industry Growth Insights published a new data on “Next-Generation Breast Cancer Diagnostic and Screening Market”. The research report is titled “Next-Generation Breast Cancer Diagnostic and Screening Market research by Types (Real-Time PCR (q-PCR), Immunohistochemistry (IHC), Next-Generation Sequencing (NGS), Fluorescent In-Situ Hybridization (FISH)), By Applications (Hospital-associated Labs, Cancer Research Institutes, Diagnostic Centers), By Players/Companies Abbott Laboratories, Agendia, Agilent Technologies, Ambry Genetics, Biocept, Biotheranostics, Centogene, Danaher Corporation, EXACT Sciences Corporation, Roche Holding AG, Fulgent Genetics, Illumina, Invitae, Lucence Diagnostics Pte Ltd, Myriad Genetics”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Next-Generation Breast Cancer Diagnostic and Screening Market Research Report
By Type
Real-Time PCR (q-PCR), Immunohistochemistry (IHC), Next-Generation Sequencing (NGS), Fluorescent In-Situ Hybridization (FISH)
By Application
Hospital-associated Labs, Cancer Research Institutes, Diagnostic Centers
By Companies
Abbott Laboratories, Agendia, Agilent Technologies, Ambry Genetics, Biocept, Biotheranostics, Centogene, Danaher Corporation, EXACT Sciences Corporation, Roche Holding AG, Fulgent Genetics, Illumina, Invitae, Lucence Diagnostics Pte Ltd, Myriad Genetics
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
244
Number of Tables & Figures
171
Customization Available
Yes, the report can be customized as per your need.
Global Next-Generation Breast Cancer Diagnostic and Screening Market Report Segments:
The global Next-Generation Breast Cancer Diagnostic and Screening market is segmented on the basis of:
Types
Real-Time PCR (q-PCR), Immunohistochemistry (IHC), Next-Generation Sequencing (NGS), Fluorescent In-Situ Hybridization (FISH)
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital-associated Labs, Cancer Research Institutes, Diagnostic Centers
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Abbott Laboratories
- Agendia
- Agilent Technologies
- Ambry Genetics
- Biocept
- Biotheranostics
- Centogene
- Danaher Corporation
- EXACT Sciences Corporation
- Roche Holding AG
- Fulgent Genetics
- Illumina
- Invitae
- Lucence Diagnostics Pte Ltd
- Myriad Genetics
Highlights of The Next-Generation Breast Cancer Diagnostic and Screening Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Real-Time PCR (q-PCR)
- Immunohistochemistry (IHC)
- Next-Generation Sequencing (NGS)
- Fluorescent In-Situ Hybridization (FISH)
- By Application:
- Hospital-associated Labs
- Cancer Research Institutes
- Diagnostic Centers
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Next-Generation Breast Cancer Diagnostic and Screening Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Next-generation breast cancer diagnostic and screening technologies are those that use more sensitive and specific methods to identify breast cancer. These technologies may include new blood tests, imaging techniques, or genetic tests.
Some of the major players in the next-generation breast cancer diagnostic and screening market are Abbott Laboratories, Agendia, Agilent Technologies, Ambry Genetics, Biocept, Biotheranostics, Centogene, Danaher Corporation, EXACT Sciences Corporation, Roche Holding AG, Fulgent Genetics, Illumina, Invitae, Lucence Diagnostics Pte Ltd, Myriad Genetics.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Next-Generation Breast Cancer Diagnostic and Screening Market Overview 4.1 Introduction 4.1.1 Market Taxonomy 4.1.2 Market Definition 4.1.3 Macro-Economic Factors Impacting the Market Growth 4.2 Next-Generation Breast Cancer Diagnostic and Screening Market Dynamics 4.2.1 Market Drivers 4.2.2 Market Restraints 4.2.3 Market Opportunity 4.3 Next-Generation Breast Cancer Diagnostic and Screening Market - Supply Chain Analysis 4.3.1 List of Key Suppliers 4.3.2 List of Key Distributors 4.3.3 List of Key Consumers 4.4 Key Forces Shaping the Next-Generation Breast Cancer Diagnostic and Screening Market 4.4.1 Bargaining Power of Suppliers 4.4.2 Bargaining Power of Buyers 4.4.3 Threat of Substitution 4.4.4 Threat of New Entrants 4.4.5 Competitive Rivalry 4.5 Global Next-Generation Breast Cancer Diagnostic and Screening Market Size & Forecast, 2018-2028 4.5.1 Next-Generation Breast Cancer Diagnostic and Screening Market Size and Y-o-Y Growth 4.5.2 Next-Generation Breast Cancer Diagnostic and Screening Market Absolute $ Opportunity
Chapter 5 Global Next-Generation Breast Cancer Diagnostic and Screening Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Next-Generation Breast Cancer Diagnostic and Screening Market Size Forecast by Type
5.2.1 Real-Time PCR (q-PCR)
5.2.2 Immunohistochemistry (IHC)
5.2.3 Next-Generation Sequencing (NGS)
5.2.4 Fluorescent In-Situ Hybridization (FISH)
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Next-Generation Breast Cancer Diagnostic and Screening Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Next-Generation Breast Cancer Diagnostic and Screening Market Size Forecast by Applications
6.2.1 Hospital-associated Labs
6.2.2 Cancer Research Institutes
6.2.3 Diagnostic Centers
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Next-Generation Breast Cancer Diagnostic and Screening Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Next-Generation Breast Cancer Diagnostic and Screening Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Next-Generation Breast Cancer Diagnostic and Screening Analysis and Forecast
9.1 Introduction
9.2 North America Next-Generation Breast Cancer Diagnostic and Screening Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Next-Generation Breast Cancer Diagnostic and Screening Market Size Forecast by Type
9.6.1 Real-Time PCR (q-PCR)
9.6.2 Immunohistochemistry (IHC)
9.6.3 Next-Generation Sequencing (NGS)
9.6.4 Fluorescent In-Situ Hybridization (FISH)
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Next-Generation Breast Cancer Diagnostic and Screening Market Size Forecast by Applications
9.10.1 Hospital-associated Labs
9.10.2 Cancer Research Institutes
9.10.3 Diagnostic Centers
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Next-Generation Breast Cancer Diagnostic and Screening Analysis and Forecast
10.1 Introduction
10.2 Europe Next-Generation Breast Cancer Diagnostic and Screening Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Next-Generation Breast Cancer Diagnostic and Screening Market Size Forecast by Type
10.6.1 Real-Time PCR (q-PCR)
10.6.2 Immunohistochemistry (IHC)
10.6.3 Next-Generation Sequencing (NGS)
10.6.4 Fluorescent In-Situ Hybridization (FISH)
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Next-Generation Breast Cancer Diagnostic and Screening Market Size Forecast by Applications
10.10.1 Hospital-associated Labs
10.10.2 Cancer Research Institutes
10.10.3 Diagnostic Centers
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Next-Generation Breast Cancer Diagnostic and Screening Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Next-Generation Breast Cancer Diagnostic and Screening Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Next-Generation Breast Cancer Diagnostic and Screening Market Size Forecast by Type
11.6.1 Real-Time PCR (q-PCR)
11.6.2 Immunohistochemistry (IHC)
11.6.3 Next-Generation Sequencing (NGS)
11.6.4 Fluorescent In-Situ Hybridization (FISH)
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Next-Generation Breast Cancer Diagnostic and Screening Market Size Forecast by Applications
11.10.1 Hospital-associated Labs
11.10.2 Cancer Research Institutes
11.10.3 Diagnostic Centers
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Next-Generation Breast Cancer Diagnostic and Screening Analysis and Forecast
12.1 Introduction
12.2 Latin America Next-Generation Breast Cancer Diagnostic and Screening Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Next-Generation Breast Cancer Diagnostic and Screening Market Size Forecast by Type
12.6.1 Real-Time PCR (q-PCR)
12.6.2 Immunohistochemistry (IHC)
12.6.3 Next-Generation Sequencing (NGS)
12.6.4 Fluorescent In-Situ Hybridization (FISH)
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Next-Generation Breast Cancer Diagnostic and Screening Market Size Forecast by Applications
12.10.1 Hospital-associated Labs
12.10.2 Cancer Research Institutes
12.10.3 Diagnostic Centers
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Next-Generation Breast Cancer Diagnostic and Screening Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Next-Generation Breast Cancer Diagnostic and Screening Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Next-Generation Breast Cancer Diagnostic and Screening Market Size Forecast by Type
13.6.1 Real-Time PCR (q-PCR)
13.6.2 Immunohistochemistry (IHC)
13.6.3 Next-Generation Sequencing (NGS)
13.6.4 Fluorescent In-Situ Hybridization (FISH)
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Next-Generation Breast Cancer Diagnostic and Screening Market Size Forecast by Applications
13.10.1 Hospital-associated Labs
13.10.2 Cancer Research Institutes
13.10.3 Diagnostic Centers
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Next-Generation Breast Cancer Diagnostic and Screening Market: Competitive Dashboard
14.2 Global Next-Generation Breast Cancer Diagnostic and Screening Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Abbott Laboratories
14.3.2 Agendia
14.3.3 Agilent Technologies
14.3.4 Ambry Genetics
14.3.5 Biocept
14.3.6 Biotheranostics
14.3.7 Centogene
14.3.8 Danaher Corporation
14.3.9 EXACT Sciences Corporation
14.3.10 Roche Holding AG
14.3.11 Fulgent Genetics
14.3.12 Illumina
14.3.13 Invitae
14.3.14 Lucence Diagnostics Pte Ltd
14.3.15 Myriad Genetics